MITI Posts -- BloggingStocks

MITI posts

Analyst upgrades, downgrades and initiations: PEP, AXP, RTP, WSM, RIMM, HPQ ...

Analyst upgrades:

JMP Securities upgraded CB Richard Ellis (NYSE: CBG) to Outperform from Market Perform. The analyst believes the new Public-Private Investment Program will create liquidity, which will result in some degree of activity. Shares were also upgraded at JP Morgan to Overweight from Neutral.
Thomas Weisel upgraded Linear Tech (NASDAQ: LLTC) to Overweight from Market Weight due to stabilizing business and favorable end market exposure.
UBS upgraded PepsiCo (NYSE: PEP) to Buy from Neutral and raised its target to $60 from $57 due to moderating input costs, earnings and investment flexibility, improving U.S. beverage business, and leverage from its market share in food.
Tibco (NASDAQ: TIBX) was raised to Buy from Neutral at Goldman.
Philips Electronics (NYSE: PHG) was upgraded at ING Group to Buy from Hold.
Hospira (NYSE: HSP) was upgraded to Outperform from Market Perform at Leerink.

MOST NOTEWORTHY: Beckman Coulter, BT Group and Micromet were today's noteworthy initiations:

Oppenheimer believes Beckman Coulter (NYSE:BEC) is well-positioned to leverage its broad installed base in the clinical lab market to increase sales of its consumable and a new molecular diagnostics instrument expected in 2010. The firm initiated shares with an Outperform rating and $80 target.
Societe Generale expects BT Group's (NYSE:BT) domestic revenues to deteriorate as line erosion accelerates; shares were assumed with a Sell rating.
Roth Capital started Micromet (NASDAQ:MITI) with a Buy rating and $3 target. The firm expects the company's proprietary 'BiTE' antibody platform to gain validation as its lead candidate MT103 starts accumulating clinical data in multiple hematology indications.

OTHER INITIATIONS:

Yahoo! (NASDAQ:YHOO) was initiated with a Neutral rating at Merrill.
Piper resumed coverage of Alexion Pharma (NASDAQ:ALXN) with a Buy rating and $88 target.
MedAssets (NASDAQ:MDAS) was started at Jefferies with a Buy rating and $25 target.

MOST NOTEWORTHY: Abbott Lab, Fannie Mae, Freddie Mac and Micromet were today's noteworthy upgrades:

Wachovia upgraded Abbott Lab (NYSE: ABT) to Outperform from Market Perform as they believe their earlier concerns have been addressed. Past concerns included the potential for a negative outcome from the FDA panel on Xience and slowing prescription growth of lead drug Humira.
Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE) were raised to Outperform from Market Perform at Keefe Bruyette citing recent government actions to stabilize the mortgage markets.
Micromet (NASDAQ: MITI) was upgraded at RBC Capital to Outperform from Sector Perform as they expect positive data for its lead candidate, MT103, by year-end.

OTHER UPGRADES:

#	Blogger	Posts	Cmts
1	Joseph Lazzaro	101	0
2	Tom Johansmeyer	94	3
3	Connie Madon	50	0
4	Steven Mallas	42	0
5	Mark Fightmaster	39	0
6	Tom Taulli	38	0
7	Steven Halpern	29	0
8	Trey Thoelcke	28	0
9	Melly Alazraki	25	0
10	Zac Bissonnette	23	0
11	Paul Foster	23	0
12	Jim Cramer	20	0
13	Brent Archer	20	0
14	Jon Ogg	20	0
15	Brian White	20	0
16	Eric Buscemi	17	0
17	Elizabeth Harrow	17	0
18	Sheldon Liber	13	0
19	Beth Gaston Moon	8	0
20	Michael Fowlkes	7	0

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.